
|Articles|April 1, 2004
Role for rexinoids is expanding
Waikoloa, Hawaii - Rexinoids such as bexarotene have promise as an adjunct to other immune response modifiers in the treatment of patients with progressive cutaneous T-cell lymphoma (CTCL), according to Jacqueline M. Junkins-Hopkins, M.D. Such therapies are typically used in combination with interferon-alpha as well as with psoralen ultraviolet-A (PUVA) and extracorporeal photopheresis (ECP).
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Grants Breakthrough Therapy Designation to Litifilimab for Cutaneous Lupus Erythematosus
2
How Galderma is Modernizing Aesthetic Trends and Patient Outcomes Around the World
3
Del Rosso's What's New in the Medicine Chest 2026: CHE, CSU, and Vitiligo
4
Dermatology Times January 2026 Print Recap
5










